Financial releases

CROSSJECT enters into partnering agreement with Sayre Therapeutics to commercialize ZENEO® Methotrexate in India

CROSSJECTconfirms the development plan for ZENEO® Sumatriptan

Crossject Reports Positive results from bioequivalence study with needle free ZENEO® Methotrexate

Crossject announces S1 2014 business update

Crossject Appoints Henri de Parseval as Supply Chain Director

CROSSJECT launches bioequivalence clinical study with ZENEO® Methrotrexate

CROSSJECT: First step of the industrialization of ZENEO®